Over the past five years, medical imaging enterprises have learned the hard way that adaptability and flexibility are prized qualities required for survival. They have weathered reimbursement cuts, increased scrutiny and the general feeling that they are ceding control of their businesses to outside agencies with agendas and motivations far different than theirs. What was once a smooth operation providing key medical information is now a daily battle to maintain viability.

Imaging the inflammatory response with PET could provide more information about traumatic brain injury (TBI) than conventional CT and MRI methods, according to research presented during the Military Health System Research Symposium held in Ft. Lauderdale, Fla., Aug. 12.

Undergoing a pretreatment PET/CT scan has shown to have more predictive value than conventional follow-up protocol for colorectal cancer with metastases to the liver and could be the case for other cancers, according to a study published Oct. 17 in the Journal of Nuclear Medicine.

Purchase a vendor-neutral archive (VNA). Design it to store DICOM and non–DICOM images. Integrate it seamlessly with electronic medical record (EMR) system. Watch its users visually enrich their patients’ medical records.

The FDA today cleared a new PET amyloid imaging agent—F-18 flutemetamol (Vizamyl). The addition of Vizamyl provides more options for dementia experts evaluating amyloid in the brain to rule out Alzheimer’s and other neurodegenerative disease.

The cognitive symptoms of autism spectrum disorder (ASD) may be due to changes in neuronal microstructures in the brain, according to a review in the October 2013 issue of Frontiers in Human Neuroscience.

Quantitative imaging with either SPECT or MR reveals the path of microspheres following liver radioembolization and could one day predict success of therapy, according to a study published Oct. 17 in the Journal of Nuclear Medicine.

An estimated 25 percent of radiation oncologists were already prescribing Radium-223 dichloride (Ra-223) injection, otherwise known as Xofigo, for metastatic castration-resistant prostate cancer one month after its launch, according to a market research report published Sept. 16 by BioTrends Research Group.